Friday, 16 October 2026European Markets

FIN.OUEST AFRICAIN Stock 9.38% Up Today

Loading stream...

(vianews) - the market ended the session with fin.ouest africain (foaf.pa) rising 9.38% to €35.00 on tuesday while cac 40 fell 0.38% to €7,267.93.

about fin.ouest africain

fin.ouest africain provides various financial services. it offers car, personal, business risk, transportation, and other property and casualty insurance products; and life insurance products for individuals, private and public companies, and organizations. it also invests in bonds and shares in listed and unlisted companies; and provides wealth management services, including building and managing real estate assets. the company was founded in 1951 and is based in dakar, senegal.

volatility

fin.ouest africain's last week, last month's, and last quarter's current intraday variation average was 20.46%, 13.04%, and 17.41%.

fin.ouest africain's highest amplitude of average volatility was 20.46% (last week), 16.28% (last month), and 17.41% (last quarter).

volume

today's last reported volume for fin.ouest africain is 117 which is 18.18% below its average volume of 143.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, fin.ouest africain's stock is considered to be oversold (<=20).

more news about fin.ouest africain (foaf.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com